Helicobacter Test

The Helicobacter Test is a diagnostic kit containing the active ingredient 13C‑Urea, designed for oral administration to detect Helicobacter pylori infection. It is marketed in the European Union and supplied as a single‑use breath test kit. The test utilizes a non‑radioactive isotope to assess urease activity associated with H. pylori, providing a non‑invasive diagnostic option. The kit includes calibrated substrates, collection devices, and detailed instructions for clinical or laboratory use.

The 13C‑Urea Breath Test is employed primarily to identify active infection with Helicobacter pylori, a bacterium linked to gastritis, peptic ulcer disease, and gastric cancer risk.

- Screening patients with dyspeptic symptoms for H. pylori infection. - Confirming eradication after antibiotic therapy. - Assessing infection status before initiating long‑term proton pump inhibitor treatment. - Supporting epidemiological studies of H. pylori prevalence. - Guiding clinical decisions in patients with a history of gastric ulcer or MALT lymphoma.

The 13C‑Urea Breath Test is generally well tolerated, but some individuals may experience mild or, rarely, more serious reactions.

Common: - Transient metallic or bitter taste in the mouth. - Mild nausea or stomach discomfort. - Increased belching or flatulence after ingestion of the test substrate.

Serious: - Allergic reaction such as rash, itching, or swelling. - Severe abdominal pain or cramping. - Respiratory difficulty or wheezing indicative of an anaphylactic response.

When using the 13C‑Urea Breath Test, certain precautions should be observed to ensure accurate results and patient safety.

- Patients should fast for at least 2 hours before the test unless instructed otherwise. - Recent use of antibiotics, bismuth compounds, or proton pump inhibitors may affect test accuracy; a washout period is often recommended. - Individuals with known urea metabolism disorders should discuss the test with a healthcare professional. - Pregnant or lactating women should be evaluated for potential risks before testing. - Ensure proper collection and handling of breath samples to avoid contamination.

The test substrate can interact with certain medications or substances, potentially influencing the result or causing adverse effects.

Avoid: - Antibiotics (e.g., clarithromycin, amoxicillin) taken within 2–4 weeks prior to testing. - Proton pump inhibitors or H2‑receptor antagonists used within 1–2 weeks before the test. - Bismuth‑containing compounds (e.g., Pepto‑Bismol) within the preceding week.

Use with caution: - Recent use of non‑steroidal anti‑inflammatory drugs (NSAIDs) that may cause gastric irritation. - Herbal supplements affecting gastric pH, such as antacids or proton‑pump‑inhibiting herbs. - Patients with severe renal or hepatic impairment should be monitored.